UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1413-3
Program Prior Authorization/Notification
Medication Joenja® (leniolisib)
P&T Approval Date 5/2023, 5/2024, 5/2025
Effective Date 8/1/2025
1. Background:
Joenja (leniolisib) is a kinase inhibitor indicated for the treatment activated phosphoinositide 3-
kinase delta (PI3Kẟ) syndrome (APDS) in adult and pediatric patients 12 years of age and older.
2. Coverage Criteriaa:
A. Initial Authorization
1. Joenja will be approved based upon both of the following criteria:
a. Diagnosis of activated phosphoinositide 3-kinase delta syndrome (APDS)
-AND-
b. Patient is 12 years of age or older
Authorization will be issued for 12 months.
B. Reauthorization
1. Joenja will be approved based on the following criterion:
a. Documentation of positive clinical response to Joenja therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
© 2025 UnitedHealthcare Services, Inc.
1
4. Reference:
1. Joenja [package insert]. Foster City, CA: Pharming Technologies, Inc.; March 2023.
Program Prior Authorization/Notification - Joenja (leniolisib)
Change Control
5/2023 New program
5/2024 Annual review. Updated initial authorization duration to 12 months.
5/2025 Annual review with no changes.
© 2025 UnitedHealthcare Services, Inc.
2